Clinical trial
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade…
NCT00002779 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00002779 |
|---|---|
| Title | Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma |
| Official title | PHASE II TRIAL OF FLUDARABINE AND SANDOSTATIN FOR RELAPSED LOW-GRADE NON-HODGKIN'S LYMPHOMA |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | fludarabine phosphate, octreotide acetate |
| Enrollment | 34 |
| Start date | Feb 1, 1998 |
| Primary completion | Jul 1, 2000 |
| Completion | Jun 1, 2015 |
| First posted | Jul 29, 2004 |
| Last update posted | Dec 15, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: